Heart failure in diabetes: effects of anti-hyperglycemic drug therapy
Abstract
Studies on the cardiovascular safety of new anti-diabetic drugs have drawn attention to the problem of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). This has included one controversial study about hospitalization associated with HF in patients treated with dipeptidyl-peptidase-4 inhibitors (I-DPP4) compared with placebo. Until recently, HF was not considered to be a vascular or chronic complication of diabetes. It is well known that patients with T2DM generally have a higher risk of developing HF. In addition, the mortality risk of patients with HF and diabetes is significantly higher than that among patients with HF without carbohydrate metabolism disorders. Among patients with HF, hyperglycaemia requiring anti-diabetic therapy is much more common than among patients without HF. Therefore, it is important to address this issue in terms of the pathogenesis of HF in patients with T2DM, the influence and dynamics of glycaemic control and methods to achieve glycaemic control, including the selection of various types of anti-diabetic drugs.
About the Authors
Gagik R. Galstyan
Endocrinology research centre
Russian Federation
Competing Interests:
Russian Federation
MD, PhD, Professor
Competing Interests:
No conflict of interest
Mikhail Y. Gilyarov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests:
Russian Federation
MD, PhD, assistant professor
Competing Interests:
No conflict of interest
References
1. International Diabetes Federation. 7th edition Diabetes Atlas. 2015. Available from: http://www.idf.org/diabetesatlas
2. Seshasai SR, Kaptoge S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. doi: 10.1056/NEJMoa1008862
3. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523. doi: 10.1056/NEJMoa1310799
4. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol. 1974;34(1):29-34. doi: 10.1016/0002-9149(74)90089-7
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet.1998;352(9131):837-853. doi: 10.1016/s0140-6736(98)07019-6
6. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377-1385. doi: 10.1093/eurheartj/ehn153
7. Bell DSH. Heart Failure: The frequent, forgotten, and often fatal complication of diabetes. Diabetes Care. 2003;26(8):2433-2441. doi: 10.2337/diacare.26.8.2433
8. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and Cardiovascular Disease : A Statement for Healthcare Professionals From the American Heart Association. Circulation. 1999;100(10):1134-1146. doi: 10.1161/01.cir.100.10.1134
9. Chou E. Decreased Cardiac Expression of Vascular Endothelial Growth Factor and Its Receptors in Insulin-Resistant and Diabetic States: A Possible Explanation for Impaired Collateral Formation in Cardiac Tissue. Circulation. 2002;105(3):373-379. doi: 10.1161/hc0302.102143
10. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol. 1989;14(1):49-57. doi: 10.1016/0735-1097(89)90053-3
11. Stratton IM. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. doi: 10.1136/bmj.321.7258.405
12. Control G, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-2298. doi: 10.1007/s00125-009-1470-0
13. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J.2006;151(1):91. doi: 10.1016/j.ahj.2005.10.008
14. Tomova GS, Nimbal V, Horwich TB. Relation between hemoglobin a(1c) and outcomes in heart failure patients with and without diabetes mellitus. Am J Cardiol. 2012;109(12):1767-1773. doi: 10.1016/j.amjcard.2012.02.022
15. Maru S, Koch GG, Stender M, et al. Antidiabetic Drugs and Heart Failure Risk in Patients With Type 2 Diabetes in the U.K. Primary Care Setting. Diabetes Care. 2004;28(1):20-26. doi: 10.2337/diacare.28.1.20
16. Diabetic Retinopathy After Two Years of Intensified Insulin Treatment. JAMA. 1988;260(1):37. doi: 10.1001/jama.1988.03410010045032
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/NEJM199309303291401
18. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. The Lancet. 2015;385(9982):2107-2117. doi: 10.1016/s0140-6736(14)61402-1
19. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med. 2005;11(8):861-866. doi: 10.1038/nm1278
20. Karalliedde J, Buckingham RE. Thiazolidinediones and their Fluid-Related Adverse Effects. Drug Saf. 2007;30(9):741-753. doi: 10.2165/00002018-200730090-00002
21. Emoto M, Fukuda N, Nakamori Y, et al. Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. Diabetologia.2006;49(9):2217-2218. doi: 10.1007/s00125-006-0313-5
22. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.The Lancet. 2007;370(9593):1129-1136. doi: 10.1016/s0140-6736(07)61514-1
23. Horita S, Seki G, Yamada H, et al. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens. 2011;2011:391762. doi: 10.4061/2011/391762
24. Raskin P, Rendell M, Riddle MC, et al. A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes. Diabetes Care. 2001;24(7):1226-1232. doi: 10.2337/diacare.24.7.1226
25. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65-75. doi: 10.1093/eurheartj/ehi555
26. Mangiavacchi M, Gasparini M, Genovese S, et al. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. Pacing Clin Electrophysiol. 2008;31(11):1425-1432. doi: 10.1111/j.1540-8159.2008.01206.x
27. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10(7):703-708. doi: 10.1016/j.ejheart.2008.05.013
28. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46(2):145-154. doi: 10.1007/s00592-008-0090-3
29. Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731. doi: 10.1136/bmj.b4731
30. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162
31. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-1326. doi: 10.1056/NEJMoa1307684
32. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-1335. doi: 10.1056/NEJMoa1305889
33. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-242. doi: 10.1056/NEJMoa1501352
34. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-1588. doi: 10.1161/CIRCULATIONAHA.114.010389
35. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. The Lancet. 2015;385(9982):2067-2076. doi: 10.1016/s0140-6736(14)62225-x
36. McMurray J. The vildagliptin in Ventricular Dysfunction Diabetes trial (VIVIDD). Proceedings of the European Heart Failure Congress. Lisbon, Portugal; 2013.
37. Yu OHY, Filion KB, Azoulay L, et al. Incretin-Based Drugs and the Risk of Congestive Heart Failure. Diabetes Care. 2015;38(2):277-284. doi: 10.2337/dc14-1459
38. Robert P. Hoffman BSP. Sympathetic Mechanisms of Hypoglycemic Counterregulation. Curr Diabetes Rev. 2007;3(3):185-193. doi: 10.2174/157339907781368995.
39. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension.2010;56(4):728-733. doi: 10.1161/HYPERTENSIONAHA.110.156554
40. Pfeffer MA, et al. The evaluation of lixisenatide in acute coronary syndrome—the results of the ELIXA trial. Symposium at the 75th Scientific Sessions of the American Diabetes Association; Boston, MA; June 8, 2015.
41. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Dapagliflozin BMS-512148. Dec 12, 2013. Available from: http://www.fda.gov/downloads.
42. Zhou L, Cryan EV, D’Andrea MR, et al. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem. 2003;90(2):339-346. doi: 10.1002/jcb.10631
43. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease states. Cardiovasc Res. 2009;84(1):111-118. doi: 10.1093/cvr/cvp190
Supplementary files
Review
For citations:
Galstyan G.R., Gilyarov M.Y. Heart failure in diabetes: effects of anti-hyperglycemic drug therapy. Diabetes mellitus. 2016;19(3):229-236. (In Russ.)
Views:
2239
Email this article 
